文献速递胸部肿瘤放疗

广泛期小细胞肺癌一线化免治疗后胸部放疗的时机、分割与剂量

Timing, fractionation, and dose of thoracic radiotherapy in patients with extensive-stage small cell lung cancer undergoing first-line Chemo-Immunotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-02-05

这项多中心回顾性研究纳入280例对一线化免治疗有效的广泛期小细胞肺癌患者,比较同步与序贯胸部放疗的疗效与安全性。序贯组无进展生存和总生存优于同步组且不良事件更少;同步组中低tBED(≤50 Gy)与更好生存相关。

要点

  • 序贯胸部放疗较同步化免放疗PFS和OS更优且不良事件更少。
  • 同步组中tBED≤50 Gy与更好OS和PFS相关。
  • 年龄、KPS、tBED和远处转移状态为独立预后因素。

核心结论

  • 基于疗效和安全性,一线化免治疗后序贯胸部放疗优于同步给予。
  • 关于最佳剂量和分割方案的探索性结论尚需进一步研究证实。

研究设计与样本

  • 多中心回顾性分析纳入2020年1月至2024年7月间接受化免治疗和胸部放疗的280例广泛期小细胞肺癌患者。
  • 按胸部放疗时机分为同步化免放疗组(CCIRT,化免期间)和序贯化免放疗组(SCIRT,化免之后),并比较不同处方剂量与分割方案。
  • 采用倾向性评分匹配(PSM)以减少选择偏倚,评估总生存(OS)、无进展生存(PFS)和治疗相关不良事件(TRAEs)。

主要发现

  • 研究总体中位PFS为8.7个月,中位OS为20.6个月。
  • SCIRT组较CCIRT组PFS更优(p = 0.008)且OS更优(p = 0.048),TRAEs发生率更低。
  • CCIRT组中低时间校正生物有效剂量(tBED,≤50 Gy)与更好OS(p = 0.028)和PFS(p = 0.014)相关。
  • 性别、KPS、tBED、脑转移状态等为TRAEs的独立影响因素。
  • 年龄、KPS、tBED和远处转移状态为独立预后因素。

关键数值与推荐

  • 同步化免放疗组中tBED≤50 Gy与更好OS(p = 0.028)和PFS(p = 0.014)相关。
  • 序贯化免放疗组较同步组PFS p = 0.008、OS p = 0.048,且TRAEs发生率更低。

临床怎么用

  • 对一线化免治疗有效的广泛期小细胞肺癌患者,可优先考虑序贯胸部放疗以改善生存并降低不良事件。
  • 若采用同步化免放疗,低tBED(≤50 Gy)可能与更好生存相关,但最佳剂量分割尚待证实。

局限性

  • 为回顾性研究,尽管采用倾向性评分匹配,仍可能存在选择偏倚。
  • 最佳剂量和分割方案的结论为探索性,需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study investigates the optimal timing, fractionation, and dose of thoracic radiotherapy (RT) in extensive-stage small cell lung cancer (ES-SCLC) patients responsive to first-line Chemo-Immunotherapy (CIT), and evaluates efficacy and safety. MATERIALS AND METHODS: In this multicenter retrospective analysis, 280 ES-SCLC patients receiving both CIT and TRT between January 2020 and July 2024 were included. Patients were stratified by TRT timing into Concurrent Chemo-Immuno-Radiotherapy (CCIRT, during CIT) or Sequential CIRT (SCIRT, after CIT) groups. We also evaluated the differences among various prescribed radiation doses and fractionation regimens. To avoid selection bias, we conducted Propensity Score Matching (PSM) for patients. Overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (TRAEs) were assessed and compared. RESULTS: The median PFS and OS in the study were 8.7 months and 20.6 months, respectively. The SCIRT group demonstrated superior PFS (p = 0.008) and OS (p = 0.048) compared with the CCIRT group, and additionally with a lower incidence of TRAEs. In the CCIRT group, a low time-corrected biological effective dose (tBED) (≤50 Gy) was associated with better OS (p = 0.028) and PFS (p = 0.014). Sex, KPS, tBED, brain metastasis status, and other indicators were independent influencing factors for TRAEs. Age, KPS, tBED, and distant metastasis status were independent prognostic factors. CONCLUSION: Based on the efficacy and safety profile, sequential TRT after first-line chemoimmunotherapy is superior to concurrent administration. The exploratory conclusions regarding the optimal dose and fractionation regimen require confirmation through further research.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou H, Zhao H, Shi S, et al. Timing, fractionation, and dose of thoracic radiotherapy in patients with extensive-stage small cell lung cancer undergoing first-line Chemo-Immunotherapy. Clin Transl Radiat Oncol. 2026. PMID: 41704721. doi:10.1016/j.ctro.2026.101114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。